Pfizer (NYSE: PFE) and Teva Pharmaceutical Industries (NYSE: TEVA) just reported third-quarter earnings that reveal two pharmaceutical companies moving in opposite directions.
Pfizer's stock rebounded from April lows yet still trades as if COVID and patent cliffs equal business ruin, despite resilient non‑COVID franchises and pipeline optionality. Q3 looked weak, with revenue and EPS down year-over-year, yet both beat estimates as Vyndaqel, Nurtec, and Padcev collectively offset fading COVID contributions. Pfizer's adjusted margin stayed near seventy‑six percent, and OPEX fell, while a $1.5 billion manufacturing optimization program should expand margins and earnings by 2027.
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock?
| Pharmaceuticals Industry | Healthcare Sector | Albert Bourla CEO | XBER Exchange | US7170811035 ISIN |
| US Country | 81,000 Employees | 7 Nov 2025 Last Dividend | 17 Nov 2020 Last Split | 13 Aug 2012 IPO Date |
Pfizer Inc. is a global biopharmaceutical company with a rich history dating back to 1849. Based in New York, New York, Pfizer has established itself as a leader in the discovery, development, manufacture, marketing, distribution, and sale of innovative biopharmaceutical products. Serving a wide range of therapeutic areas, Pfizer's portfolio includes medicines and vaccines that address a variety of health concerns, from cardiovascular metabolic conditions and infectious diseases to chronic immune and inflammatory diseases. The company has a significant global footprint, operating across the United States, Europe, and other international markets, catering to wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and more. Through strategic collaboration agreements with entities like Bristol-Myers Squibb Company, Astellas Pharma US, Inc., Merck KGaA, and BioNTech SE, Pfizer continues to lead in the development of medical breakthroughs for unmet medical needs.